We pioneer transformative therapies for rare diseases—combining innovation, clinical excellence, and patient-centric care.
We are a fast-rising biotechnology startup committed to advancing science and patient care since our inception.
Founded in New York City with a mission to develop serine protease inhibitors targeting rare, underserved diseases.
Initiated development of ATN-249, our flagship molecule addressing Hereditary Angioedema (HAE).
Expanded research into complement pathway diseases, evolving into a multi-program pipeline company.
Positive preclinical results for ATN-249 supported its transition into Phase 1 development.
Phase 1 clinical trials begun and domain rebrand to attunepharmaceutical.com for legal and clinical clarity.
Patent Families Filed
(3 In‑Licensed)
Trademarks Filed
Financing Raised
Continents Impacted
Guided by principles that reflect our responsibility to patients, partners, and science.
Continuously innovating to address unmet needs in rare diseases.
Upholding the highest ethical standards in research and business.
Empathetically improving lives through safe, effective therapies.